Cargando…

Autoantibodies neutralizing type I interferons in 20% of COVID-19 deaths in a French hospital

Mostrar otras versiones (1)

Recent studies reported the presence of pre-existing autoantibodies (auto-Abs) neutralizing type I interferons (IFNs) in at least 15% of patients with critical or severe COVID-19 pneumonia. In one study, these auto-Abs were found in almost 20% of deceased patients across all ages. We aimed to assess...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chauvineau-Grenier, Angélique, Bastard, Paul, Servajean, Antoine, Gervais, Adrian, Rosain, Jérémie, Jouanguy, Emmanuelle, Cobat, Aurélie, Casanova, Jean-Laurent, Rossi, Benjamin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Journal Experts 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491850/ https://www.ncbi.nlm.nih.gov/pubmed/34611657 http://dx.doi.org/10.21203/rs.3.rs-915062/v1

Ejemplares similares

Autoantibodies Neutralizing Type I Interferons in 20% of COVID-19 Deaths in a French Hospital
por: Chauvineau-Grenier, Angélique, et al.
Publicado: (2022)

Autoantibodies Neutralizing Type I INFs May Be Associated with Efficacy of Tocilizumab in COVID-19 Pneumonia
por: Chauvineau-Grenier, Angélique, et al.
Publicado: (2022)

Auto-anticorps anti-interférons de type I et COVID-19 sévère
por: Bastard, Paul, et al.
Publicado: (2021)

Neutralizing Autoantibodies to Type I Interferons in COVID-19 Convalescent Donor Plasma
por: Vazquez, Sara E., et al.
Publicado: (2021)

No increased prevalence of autoantibodies neutralizing type I IFNs in idiopathic pulmonary fibrosis patients
por: Philippot, Quentin, et al.
Publicado: (2023)

Autoantibodies Neutralizing Type I IFNs in the Bronchoalveolar Lavage of at Least 10% of Patients During Life-Threatening COVID-19 Pneumonia
por: Philippot, Quentin, et al.
Publicado: (2023)

Life-Threatening COVID-19: Defective Interferons Unleash Excessive Inflammation
por: Zhang, Qian, et al.
Publicado: (2020)

Type I interferons and SARS-CoV-2: from cells to organisms
por: Bastard, Paul, et al.
Publicado: (2022)

Autoantibodies Against Type I IFNs in Patients with Ph-Negative Myeloproliferative Neoplasms
por: Borsani, Oscar, et al.
Publicado: (2021)

Pre-existing Autoantibodies Neutralizing High Concentrations of Type I Interferons in Almost 10% of COVID-19 Patients Admitted to Intensive Care in Barcelona
por: Solanich, Xavier, et al.
Publicado: (2021)

Low Lymphocytes and IFN-Neutralizing Autoantibodies as Biomarkers of COVID-19 Mortality
por: Troya, Jesús, et al.
Publicado: (2022)

Autoantibodies against type I IFNs in patients with Ph-negative myeloproliferative neoplasms
por: Borsani, Oscar, et al.
Publicado: (2022)

Neutralizing Type I Interferon Autoantibodies in Japanese Patients With Severe COVID-19
por: Eto, Shohei, et al.
Publicado: (2022)

Neutralizing Type I Interferon Autoantibodies in Japanese Patients with Severe COVID-19
por: Eto, Shohei, et al.
Publicado: (2022)

Autoantibodies neutralizing type I IFNs underlie West Nile virus encephalitis in ∼40% of patients
por: Gervais, Adrian, et al.
Publicado: (2023)

Anti-GM-CSF Neutralizing Autoantibodies in Colombian Patients with Disseminated Cryptococcosis
por: Arango-Franco, Carlos A., et al.
Publicado: (2023)

In memoriam: Stephen J Seligman, MD: Adverse reactions to the yellow fever vaccine: from epidemiological risk factors to causes and mechanisms
por: Casanova, Jean-Laurent, et al.
Publicado: (2022)

Autoantibodies against type I interferons are associated with multi-organ failure in COVID-19 patients
por: Koning, Rutger, et al.
Publicado: (2021)

Impaired thymic AIRE expression underlies autoantibodies against type I IFNs in humans with inborn errors of the alternative NF-κB pathway
por: Voyer, Tom Le, et al.
Publicado: (2023)

Human autoantibodies underlying infectious diseases
por: Puel, Anne, et al.
Publicado: (2022)

Interferon-β Therapy in a Patient with Incontinentia Pigmenti and Autoantibodies against Type I IFNs Infected with SARS-CoV-2
por: Bastard, Paul, et al.
Publicado: (2021)

Detection of homozygous and hemizygous complete or partial exon deletions by whole-exome sequencing
por: Bigio, Benedetta, et al.
Publicado: (2021)

Neutralizing Anti-interferon-γ Autoantibodies: an Ameliorating Factor in COVID-19 Infection?
por: Kacar, Mark, et al.
Publicado: (2021)

Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain
por: Troya, Jesús, et al.
Publicado: (2021)

French‐style genetics v. 2.0: The “e‐CohortE” project
por: Stoeklé, Henri‐Corto, et al.
Publicado: (2019)

Autoantibodies against type I IFNs in patients with critical influenza pneumonia
por: Zhang, Qian, et al.
Publicado: (2022)

Plasma Exchange to Rescue Patients with Autoantibodies Against Type I Interferons and Life-Threatening COVID-19 Pneumonia
por: de Prost, Nicolas, et al.
Publicado: (2021)

Neutralizing Anti-Cytokine Autoantibodies Against Interferon-α in Immunodysregulation Polyendocrinopathy Enteropathy X-Linked
por: Rosenberg, Jacob M., et al.
Publicado: (2018)

Neutralizing Activity of Anti-interferon-γ Autoantibodies in Adult-Onset Immunodeficiency Is Associated With Their Binding Domains
por: Yasamut, Umpa, et al.
Publicado: (2019)

Diagnostic and Therapeutic Challenges in Disseminated Mycobacterium colombiense Infection Caused by Interferon-γ Neutralizing Autoantibodies
por: Matono, Takashi, et al.
Publicado: (2023)

Vaccination prevents severe COVID-19 outcome in patients with neutralizing type 1 interferon autoantibodies
por: Wolff, Anette S.B., et al.
Publicado: (2023)

Autoantibodies to Interferons in Infectious Diseases
por: Quiros-Roldan, Eugenia, et al.
Publicado: (2023)

Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19
por: van der Wijst, Monique G. P., et al.
Publicado: (2021)

Disseminated Mycobacterium avium Infection Presenting with Bladder Lesions in a Patient with Interferon-γ-neutralizing Autoantibodies
por: Miyashita, Koichi, et al.
Publicado: (2018)

Disseminated Mycobacterium avium Infection Complicated with Chylous Ascites in a Patient with Neutralizing Autoantibodies to Interferon-γ
por: Yamaba, Yusuke, et al.
Publicado: (2020)

A non-HIV case with disseminated Mycobacterium kansasii disease associated with strong neutralizing autoantibody to interferon-γ
por: Nei, Takahito, et al.
Publicado: (2012)

Clinical manifestations, course, and outcome of patients with neutralizing anti-interferon-γ autoantibodies and disseminated nontuberculous mycobacterial infections
por: Chi, Chih-Yu, et al.
Publicado: (2016)

450. Type I Interferon Autoantibodies Are Detected in Those with Critical COVID-19, Including a Young Female Patient
por: Yee, Debra, et al.
Publicado: (2021)

High-titer anti-interferon-γ neutralizing autoantibodies linked to opportunistic infections in patients with adult-onset still's disease
por: Chen, Po-Ku, et al.
Publicado: (2023)

Monoclonal antibody-mediated neutralization of SARS-CoV-2 in an IRF9-deficient child
por: Lévy, Romain, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0qa8s411c54vlqf3fbp4v96cue